[Development and properties of neutralizing monoclonal antibodies for fusion protein of respiratory syncytial virus.]
Vladimir T Valuev-EllistonRegina R KlimovaNatalia E FedorovaOlga V MasalovaAleksandra NikonovaEkaterina I LesnovaE D MomotyukNatalya A DemidovaT G SamartsevaV V ZverevPublished in: Voprosy virusologii (2020)
High activity and specificity of MAbs indicate that they can serve as a basis for development vaccines and preventive medicines.
Keyphrases